Kezar Life Sciences

Rank#10277

Market Cap53.86M

CountryUnited States

Summary

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

History

Kezar Life Sciences was founded in 2015 to translate breakthrough science into novel therapeutics to treat systemic autoimmune diseases. Our pipeline includes therapies focused on systemic lupus erythematosus (SLE), a debilitating disease with no cure. We have leveraged the deep knowledge of our scientific founders to innovate and develop a growing portfolio of therapeutic programs.

Mission

Our mission is to pioneer and develop novel therapeutic solutions to improve the lives of patients with systemic autoimmune diseases.

Vision

We envision a better future in which innovative, life-changing solutions are developed to reduce the burden of systemic autoimmune diseases.

References

https://in.investing.com/equities/kezar-life-sciences

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/kezar-life-sciences

https://finance.yahoo.com/quote/KZR/

https://www.kezarlifesciences.com

https://sec.report/CIK/0001645666

Leadership team